• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Packaging Technology

    Elemental Impurities: The Time Has Come

    Continuous vs. Batch Production

    2018: The evolution of pharmaceutical packaging

    Formulation Development Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WuXi AppTec Opens Laboratory Testing Facility in NJ

    ICON, Intel Enter Pharma Analytics Platform Pact

    AMRI Renews NIH Contract

    Sterling Pharma Invests £6M To Expand Offerings

    Bioclinica Announces Key Hires & Promotion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Opens Laboratory Testing Facility in NJ

    Arcinova Receives £1.5M Innovate UK Grant

    Vetter Announces Visit from Illinois Governor

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    Almac Group Expands Packaging Capabilities

    Catalent Bolsters Clinical Supply Capabilities

    West, Stevanato Group Enter Ompi EZ-fill Alliance

    Pharmaceutical Packaging Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    WuXi AppTec Opens Laboratory Testing Facility in NJ

    ICON, Intel Enter Pharma Analytics Platform Pact

    AMRI Renews NIH Contract

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Blockchain: The Next Big Trend in BioPharma?

    Emergent Completes Market Authorization

    Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12

    LSNE Expands Capabilities and QC Laboratory Space

    Evotec Launches Drug Development Service
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Symbiosis Pharmaceutical Services

    IQVIA

    Avista Pharma Solutions

    Exelead
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Fill-Finish Innovation

    Showing Sparks of Life

    Related CONTENT
    • Future Bio-Capacity Constraints
    • Cook Pharmica Gains New FDA Approval
    • HHS Establishes Flu Vax Manufacturing Network
    • Consolidation in Outsourcing
    • Pharma & Biopharma Outsourcing Association Formed
    Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. 03.13.13
    Fill-finish processing comes after upstream bioprocessing, formation of the active agent by cell culture or fermentation, and downstream purification; this is when the final product has the greatest value, and, thus, the most to lose to a product failure. So at these later stages of development, tried-and-true processes tend to be what’s used. Innovation can introduce elements of risk, expense and regulatory work into bioprocess operations. This includes the formulation, mixing or other preparation of the active agent into its final form, e.g., liquid or lyophilized powder, and filling and sealing within final containers, which increasingly include prefilled syringes and other delivery systems.

    Fill-finish is a critical part of biopharmaceutical manufacture, and any mistakes at this point can potentially lead to product mis-formulation, contamination or improper packaging. These can result in safety issues, production failures and loss of expensive product.

    Because of this, Fill-Finish operations are often not thought of as demanding substantive innovation. The underlying nature of Fill-Finish operations today is largely mechanical, involving the moving, manipulation and packaging of liquid and solid dosage forms. Many Fill-Finish operations, such as filling of vials, are virtually unchanged from decades prior. Much is repetitive; liquid dosage forms undergo essentially the same processes and handling as most other similarly vialed pharmaceuticals. Associated with this, Fill-Finish manufacturing processes have changed relatively little in recent years and generally use the most well-established methods and equipment. Innovation in this area is something to be avoided until needed.

    New Fill-Finish Innovations 2010-2012
    Despite the relatively stable nature of the industry, areas of innovation are emerging. To identify other areas of innovation, our 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity1 asked 302 global bioprocessing directors and end-users to consider the new products and services their suppliers develop for the industry. Our objective was to identify ‘problems in need of solutions.’ We identified 21 key areas of innovation of interest to end-users, and 40 areas of innovation that suppliers to this industry are currently working on.

    When it comes to innovation, our 302 global respondents were looking at other areas in the chain, citing disposable products, including bags and connectors (40.0%), probes, sensors, etc. (36.1%), chromatography products (32.2%), bioreactors (31.7%), purification products (28.9%). Compared to these, Fill-Finish services were relatively low on the list, at 15.6% of end-users in 2012. This has remained relatively constant over the past three years.

    Figure 1: Percentage of End-users Interested in Fill-Finish Improved Products/Services: 2010 - 2012
    We also evaluated the differences between how respondents in the U.S. compared those in western Europe and the “Rest of World” in terms of their needs for solutions associated with new products or services. In Fill/Finish areas, we found that “ROW” countries were significantly more interest in fill finish services, and other services, such as formulation, validation and cell line services. These services areas are presumably lacking in “ROW” countries.

    What are Suppliers Doing About It?
    There is a growing need for improvements in Fill-Finish. Over the past couple years, we have found a notable increase in the percentage of suppliers to this industry who are investing in new technologies in Fill-Finish areas. Our global study also evaluated where industry suppliers are putting R&D resources. We separately queried 185 global vendors to identify, among other things, what investments are being made into new technologies. Of the 40 areas identified, the largest percentage was focused on creating new ‘bioprocess development services/bioprocess modeling’ (46.5%). In comparison, Fill-Finish innovation investment is relatively low on the list. However, this has grown significantly over the past year. Our data show that “Finishing: Lyophilization” and “Finishing: Packaging materials” are areas of strong investment among suppliers.

    Figure 2: Selected New Technologies Development Areas
    Innovations in Fill-Finish
    Novel delivery systems, such as complex disposable injectors and cartridge-based reusable pen injectors, have required and resulted in a number of specific associated technological advances in Fill-Finish. Filling fluids or solids into these and other types of containers and sealing these with complete lack of microbial and chemical contamination is never a simple task, and even such things as glass vials undergo constant but slow incremental innovations. Fill-finish operations also benefit from and often involve improvements in materials, such as plastics for more reliable seals and less leaching, and biologically-inert surface coatings for glass and metal container surfaces.

    Many of the innovations in Fill-Finish involve mechanical engineering, such as pushing machinery to go faster with greater throughput. Associated with this, Fill-Finish equipment manufacturers continually seek to make their machinery more efficient, reliable (lower failure rates) and cost-effective. This often involves scale-up (and, sometimes, scale-down) of machinery and operations to tailor them to the needs of specific products. CMOs perform the great majority of biopharma Fill-Finish, and thus are among the leaders in terms of actively developing, evaluating and adopting technologies and equipment that improve productivity and reduce risks of contamination and process failure.

    Fill-finish innovations include a distinct trend for increased use of isolator technology. Isolators, exemplified on a small-scale by glove boxes, and related restricted access barrier systems (RABS) with somewhat lower operating standards, essentially involve individually enclosing all the process equipment and flow within sealed, no-release, no-contamination enclosures or other physical containment. Isolators completely remove or isolate human operators from the environment surrounding the product.

    Isolators are enclosed, usually positively pressurized units with high efficiency particulate air (HEPA) filters supplying ISO 5 airflow in a unidirectional manner to the interior. Air is typically recirculated by returning it to the air handlers through sealed ductwork. There are also differences in cleaning and decontamination between RABS and isolators, with isolators operating at higher standards. This isolation of the product from the non-sterile surrounding environment and operators is particularly important for the many biologics that cannot be terminally sterilized. Many proteins are simply not capable of withstanding heating or other chemical/physical processes used for sterilization, requiring fully aseptic processing to maintain product sterility.

    By adding increased certainty regarding sterility, use of isolator technology can simplify Fill-Finish operations and reduce costs. For example, with Fill-Finish equipment individually enclosed, there is less need for equipment to be housed in large expensive high-end clean rooms. The use of fully-enclosed systems, which can now involve use of single-use bags, much as with upstream bioprocessing, serves to assure product sterility and eliminate operator-originating contamination. There are also added benefits of eliminating releases of product and occupational exposures, which can be a critical requirement with many highly potent or toxic products. Isolators or their equivalent are also being adopted for mainstream bioprocessing; Xcellerex promotes individual containment of its single-use bioreactors within glass-walled isolator enclosures. These are then housed in clean rooms operating at a lower level than would otherwise be needed.

    Patheon, a CMO involved in solid and liquid dose manufacturing and Fill-Finish, has developed a single-use tabletting process. Tony Pidgeon, senior manager, Global Science and Technology at Patheon Inc., notes that Patheon continues to develop single-use systems for Fill-Finish of clinical trial materials. Mr. Pidgeon has been involved in the design and implementation of many innovative systems for clinical trial sterile dosage forms.

    A Mature Industry Niche
    Fill-Finish for biologics is a relatively mature, primarily industrial activity, concentrating on efficient product formulation and packaging. Fill-Finish, much more than bioprocessing, involves complex mechanical engineering — filling, fluid and solid dispensing and sealing systems. Fill-finish professionals tend to more be engineers rather than scientists. And Fill-Finish professionals, like this industry, are rather conservative, seeking the safest process, including the safest in terms of lowest regulatory and business risks.

    Most of the recent dramatic innovations in bioprocessing, notably the adoption of single-use/disposable equipment and increases in product yield/output, have not moved into Fill-Finish operations (with some exceptions, such as single use storage bags, tubing, and filling tips). However, Fill-Finish was among the first areas to adopt silicone and other single-use tubing and manifolds in place of stainless steel piping. Broader issues in bioprocessing, such as the difficulties with downstream purification processes keeping up with increased upstream yields, generally do not affect Fill-Finish operations, which rarely are the major bottlenecks in product manufacture. Much as with other aspects of bioprocessing, Fill-Finish involves intermittent intensive campaigns.

    Multiple industry surveys have shown that industry decision-makers foresee few significant changes in Fill-Finish technologies in the near future. Fill-finish is not as innovation-driven as active agent development and manufacture, and many Fill-Finish operations are among the most commonly outsourced aspect of biomanufacturing. In our annual study, we estimated that Fill-Finish operations are outsourced to CMOs for about 75% of clinical and 85% of commercial biopharma supplies. Fewer than 25% of drug innovator companies now do more than 10% of their product Fill-Finish in-house. So, any current discussion of Fill-Finish generally involves discussion of CMOs, which provide the great bulk of these services, ranging from the most routine to incredibly high-tech handling and packaging.

    The Fill-Finish industry is characterized by a wide diversity in the magnitude of its operations. These range from manual filling and sealing of products for clinical trials supplies to filling and sealing of tens or even hundreds of thousands or millions of units daily, e.g., as with some vaccines. The industry perpetually faces the quandary that to be optimally cost-effective generally requires operating at the very largest scale using the fastest process lines and biggest equipment, but the higher the capacity of a facility or process line, the more likely it is to be idle much of the time.

    Compared with other aspects of bioprocessing, the Fill-Finish industry currently has much excess (unused) capacity, e.g., some equipment and processing lines may only be used a few times per year. Companies, whether primary manufacturers or CMOs, need to use and keep their equipment busy, in order to attain acceptable cost-effectiveness and return on their operations. Between current excess capacity and the need to use equipment and facilities, Fill-Finish CMOs are rather cost-competitive. Overall, other than products with specialized needs, there currently is no problem with CMO Fill-Finish capacity and availability. If anything, there appears to be excess capacity, with some industry consolidation likely to occur, particularly for CMOs offering standard processes or having insufficient or excess capacity, operating at the wrong scales, for the jobs they take on.

    Fill-Finish Industry Growth
    Fill-Finish activities and the primarily CMO-based Fill-Finish industry have been growing at the same rate as overall biopharma manufacturing, i.e., 10%-15% annually. Biosimilars are be-coming a major factor affecting more Fill-Finish CMOs. Overall, CMOs are reporting an annual 10%-15% increase in projects due to biosimilars, particularly those now in development for the U.S. market in coming years. These products reinforce the ongoing trend seen in bioprocessing of manufacturing being done at smaller scale, whether due to attaining higher yields or less product demand. With biosimilars, more companies will be manufacturing more competing products, with more projects/ products going to Fill-Finish CMOs, while the market and manufacturing requirements for the original innovator/reference products decrease. Thus, biosimilars and other follow-on products are resulting in more work for more CMOs, but at smaller scale.

    Conclusions
    Although Fill-Finish is not the most active area for biopharma innovations, it does operate at the point of highest product value, and so advances related to risk reduction, product quality, and efficiency will certainly bring improvements to this segment. Fill-finish is inherently more mechanical and repetitive than other aspects of biopharma manufacture, and innovations tend to be incremental, such as improved equipment performance. But Fill-Finish remains very critical to biopharma manufacture. Fill-finish operations are mostly performed by CMOs, which dominate what has become a distinct Fill-Finish CMO-based industry. The use of isolator technology, enclosing Fill-Finish equipment in its own contained, controlled environments, is a major ongoing trend. CMOs are among the leaders in both the development and adoption of this and other new Fill-Finish technologies, so expect more innovations in this area to result from partnerships between the CMOs and their equipment suppliers. 

    CASE EXAMPLE

    Cook Pharmica is an example of a CMO that has been significantly implementing isolator technologies. Jo Anne Jacobs, manager, Technical Sciences, Drug Products, Cook Pharmica, noted, “Regulatory bodies are demanding more stringent sterility assurance requirements, so we expect isolator technologies and single-use systems to continue to advance. Complete removal of operators from the environment surrounding the product has become the expected standard.”

    Commenting on the use of isolators vs. RABS with less-stringent isolation, Ms. Jacobs noted, “The isolator will most likely fully supplant RABS in the future. Isolator systems can be installed and operated in Grade C/D areas and allow for minimal to no sterile gowning requirements. This also leads to lower operational costs from the standpoint of utilities. RABS systems offer excellent product and personnel protection, but must be installed and operated in a Grade B space which requires traditional cleanroom gowning.”

    Cook believes that as regulatory bodies promulgate more stringent sterility assurance requirements, the use of isolator technology and single-use systems will continue to increase. Innovation in this area will support that goal, and will reduce the need for dedicated stainless steel tankage for aseptic liquid handling.

    Survey Methodology
    The 2012 Ninth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production in the series of annual evaluations by BioPlan Associates, Inc. yields a composite view and trend analysis from 302 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 29 countries. The methodology also included over 185 direct suppliers of materials, services and equipment to this industry. This year's survey covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world's major markets in the U.S. and Europe.

    Reference
    1. 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity, April 2012, BioPlan Associates, Inc. Rockville, MD www.bioplanassociates.com

    Ronald A. Rader is senior director, Technical Research, and Eric S. Langer is managing partner, both at BioPlan Associates (www.bioplanassociates.com), a biopharma marketing research and publishing company, with more than 22 years of experience evaluating this and other life sciences segments. For more information about this article, contact elanger@bioplanassociates.com or 301-921-5979. 
    Related Searches
    • Development
    • Aseptic
    • Biopharma
    • Filling
    Suggested For You
    Innovative Manufacturing Technology for Aseptic Filling Innovative Manufacturing Technology for Aseptic Filling
    Avista Pharma Spends $4mn to Upgrade Capabilities Avista Pharma Spends $4mn to Upgrade Capabilities
    Piramal Pharma Solutions Launches Expanded Capabilities in KY Piramal Pharma Solutions Launches Expanded Capabilities in KY
    Fresenius Kabi to Expand U.S. Mfg. Ops Fresenius Kabi to Expand U.S. Mfg. Ops
    Avista Expands Facility in MA Avista Expands Facility in MA
    Generic Specialties Acquires Axcellerate Pharma Generic Specialties Acquires Axcellerate Pharma
    Vetter Completes Chicago Expansion Vetter Completes Chicago Expansion
    Vetter Development Service Chicago is now ready for realizing clinical syringe projects Vetter Development Service Chicago is now ready for realizing clinical syringe projects
    Newsmakers: CMOs and CDMOs Have a Trade Association to Call Their Own Newsmakers: CMOs and CDMOs Have a Trade Association to Call Their Own
    Pharma & Biopharma Outsourcing Association Formed Pharma & Biopharma Outsourcing Association Formed
    Consolidation in Outsourcing Consolidation in Outsourcing
    HHS Establishes Flu Vax Manufacturing Network  HHS Establishes Flu Vax Manufacturing Network
    Cook Pharmica Gains New FDA Approval Cook Pharmica Gains New FDA Approval
    Future Bio-Capacity Constraints Future Bio-Capacity Constraints

    Related Features

    • Contract BioManufacturing in China: Creating a New Segment

      Contract BioManufacturing in China: Creating a New Segment

      An up-close look at China’s growing market for CMO services.
      Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18

    • cGMP Manufacture
      Biopharmaceutical Contract Manufacturing Market

      Biopharmaceutical Contract Manufacturing Market

      The market continues to grow, projected to exceed $4 billion in 2017
      William Downey, President, HighTech Business Decisions 06.06.17

    • Tracking Health

      Tracking Health

      Exploring the impact of wearable health monitoring tools on CROs
      Nigel Walker 05.09.17


    • CROs and Today’s  R&D Landscape

      CROs and Today’s R&D Landscape

      John Lewis of ACRO discusses opportunities, challenges, and the future CRO
      Kristin Brooks, Associate Editor, Contract Pharma 11.09.16

    • APIs | Clinical Trial Materials
      Choosing Oral Formulations for First-in-man Clinical Trials

      Choosing Oral Formulations for First-in-man Clinical Trials

      Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems
      Jon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16

    • Robust Assay Designs

      Robust Assay Designs

      Easing the transition from preclinical to clinical research
      Tim Wright, Editor, Contract Pharma 10.11.16


    • APIs | Clinical Trial Materials
      7 Steps Virtual Pharma Companies Can Take to Improve Clinical Study Success

      7 Steps Virtual Pharma Companies Can Take to Improve Clinical Study Success

      Virtual pharmaceutical companies face special challenges
      Joe Cobb, Anshul Gupte, Metrics Contract Services 10.11.16

    • Logistics | Serialization | Supply Chain
      Healthcare Companies Tackle Supply Chain Issues

      Healthcare Companies Tackle Supply Chain Issues

      UPS study shows logistics gains in some areas, challenges in others
      Jan Denecker, UPS Europe 06.02.16

    • APIs | Cleaning Validation | Validation
      Limiting APIs in Manufacturing Effluent

      Limiting APIs in Manufacturing Effluent

      An approach for setting limits on pharmaceuticals discharged in manufacturing effluent
      Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc. 06.02.16


    • Clinical Trial Materials
      Who’s the Right Service Provider for You?

      Who’s the Right Service Provider for You?

      Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers
      Raymond Peck, VxP Pharma Services 06.02.16

    • Aseptic Processing | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16

    • Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16

    • Fill/Finish | Parenterals | Supply Chain | Vials
      Biotech Boom Fuels Parenteral Market

      Biotech Boom Fuels Parenteral Market

      Assessing the trends driving parenteral manufacturing
      Colin MacKay, Symbiosis Pharmaceutical Services 06.02.16

    • Process Development | Supply Chain
      Biopharma CMO Market Trends

      Biopharma CMO Market Trends

      Continued strong growth in biopharma industry is being driven by biosimilars
      Tim Wright, Editor 06.02.16

    • APIs | Cleaning Validation | Risk Management | Validation
      Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

      Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

      Health-based exposure limits are needed to support risk assessments
      B.D. Naumann, P.J. Nigro, U. Bruen, L. Parola, D. Cragin and A. Schatz, Merck & Co., Inc. and Ashland, Inc. 05.05.16

    Breaking News
    • WuXi AppTec Opens Laboratory Testing Facility in NJ
    • ICON, Intel Enter Pharma Analytics Platform Pact
    • AMRI Renews NIH Contract
    • Sterling Pharma Invests £6M To Expand Offerings
    • AGC Chemicals to Feature Advanced Intermediates
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • Pharmaceutical Packaging Technology
    • Elemental Impurities: The Time Has Come
    • Continuous vs. Batch Production
    • 2018: The evolution of pharmaceutical packaging
    • Formulation Development Trends
    • Changing Dynamics: The CDMO market in focus
    • Contract BioManufacturing in China: Creating a New Segment
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.